Floatz logo

Ezetimibe

Hyperlipidemia

NewAmsterdam PharmaSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Hyperlipidemia cohort.

Asset / SponsorPhaseRating
ATORVASTATIN
Poznan University of Medical Sciences
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
PRAVASTATIN
University of North Carolina, Chapel Hill
Phase 4BBB
Darunavir
University of Colorado, Denver
Phase 4BB
Fenofibrate
Ospedale di Circolo - Fondazione Macchi
Phase 4BB

View all 35 →

Same molecule, other indications

Ezetimibe is also rated in:

coronary artery disorderDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
inherited lipid metabolism disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →